Huma Therapeutics Limited, a worldwide digital health technology business focused on developing digital-first care delivery and research to help people live longer, fuller lives, announced a new collaboration with AstraZeneca to grow digital health innovation. This new partnership between Huma and AstraZeneca shows that both companies want to improve healthcare outcomes by bridging the gap between patients and doctors through digital health tools.
Huma and AstraZeneca will collaborate to develop Software as a Medical Device companion applications for various therapeutic areas and assist in expediting the adoption of decentralized clinical trials. These will be built on Huma's proven technologies, powering digital-first care for over 1.8 million active patient users across over 3,000 hospitals and clinics. In addition, Huma's solutions are meant to work with clinical operations, which makes care delivery more efficient and saves time.
"Our track record of scaling innovation has set the stage for this important partnership with one of the world's largest biopharmaceutical companies. I am excited to have AstraZeneca's support built upon our 10-year experience of delivering digital-first solutions across healthcare and clinical trials. The combination of pioneering leadership, global-reach, deep medical knowledge, and digital innovation will enable our award-winning1 platform to help more people live longer, fuller lives."
Dan Vahdat, CEO of Huma
"This collaboration marks an important moment as it is a first for AstraZeneca in the digital health space and the industry for chronic diseases and SaMDs in support of different treatments," said Karan Arora, Chief Commercial Digital Officer, AstraZeneca. "With Huma, we are accelerating AstraZeneca's ambition to achieve earlier diagnosis and treatment for patients with chronic diseases so they can lead better, more fulfilling lives."
The necessity for more excellent digital-first care is highlighted because 95% of chronic illness treatment occurs outside of the clinical setting. AstraZeneca has invested in the development and clinical validation of the patient-centered AMAZE chronic illness management platform to enhance patient care. AstraZeneca has utilized the AMAZE platform to perform clinical research at premier academic medical institutions in the United States to strengthen patient involvement, care-team communication, and clinical results while lowering healthcare costs. There are already solid foundations and early successes at the company, so the partnership with Huma will help it move forward. It will also help the company bring in SaMDs.
"We are very excited to be working more closely with Huma across our digital health initiatives," said Ruud Dobber, Executive Vice President and President, Biopharmaceuticals Business Unit, AstraZeneca. "We believe digital can expand access to healthcare, advance clinical research, and identify existing gaps in care. Additionally, with this innovative partnership, we will bring a combination of technology and expertise in research and drug development to global decentralized clinical trials advancing the science of right patient, right therapy, right time."